Top

Published in:

01-02-2018

Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997–2011

Authors: Sarah C. Fisher, Alissa R. Van Zutphen, Paul A. Romitti, Marilyn L. Browne, for the National Birth Defects Prevention Study

Published in: Maternal and Child Health Journal | Issue 2/2018

Abstract

Background Small for gestational age (SGA) birth is associated with poor long-term health outcomes. It is unclear whether maternal antihypertensive medication increases risk of SGA independently of maternal hypertension. Methods We analyzed associations between maternal hypertension and antihypertensive medication use and SGA among non-malformed singleton controls in the National Birth Defects Prevention Study. We defined SGA as birthweight < 10th percentile for a given gestational age, sex, race/ethnicity, and parity. We included 1045 SGA and 10,019 non-SGA births. We used logistic regression to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs). We assessed interaction between hypertension, antihypertensive use, and maternal race/ethnicity and age. Results Overall, 122 (11.7%) SGA and 892 (8.9%) non-SGA mothers reported hypertension and 21 (2.0%) SGA and 154 (1.5%) non-SGA mothers reported antihypertensive use. The most commonly reported medications were centrally-acting antiadrenergics, β-blockers, calcium channel blockers, and diuretics. Compared to normotensive pregnancies, maternal hypertension, regardless of treatment (AOR, 1.49 [95% CI, 1.20, 1.86]), and untreated maternal hypertension [AOR, 1.46 (95% CI, 1.15, 1.86)] were associated with SGA. We observed a positive, but not significant, association between antihypertensive use and SGA. SGA risk varied by maternal race/ethnicity, being highest among Hispanic mothers, and age, being highest among mothers ≥ 35 years, but statistical tests for interaction were not significant. Conclusions Consistent with the literature, our findings suggest that maternal hypertension slightly increases SGA risk. We did not observe an appreciably increased SGA risk associated with antihypertensive medication use beyond that of the underlying maternal hypertension.

Available only for authorised users

Abalos, E., Duley, L., & Steyn, D. W. (2014). Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews (Online), 2, CD002252. https://doi.org/10.1002/14651858.CD002252.pub3.

Ananth, C. V., Peedicayil, A., & Savitz, D. A. (1995). Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small-for-gestational-age births. Epidemiology (Cambridge, Mass.), 6(4), 391–395.CrossRef

Andrade, S. E., Raebel, M. A., Brown, J., Lane, K., Livingston, J., Boudreau, D., … Platt, R. (2008). Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiology and Drug Safety, 17(3), 240–247. https://doi.org/10.1002/pds.1550.CrossRefPubMed

Bateman, B. T., Bansil, P., Hernandez-Diaz, S., Mhyre, J. M., Callaghan, W. M., & Kuklina, E. V. (2012). Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. American Journal of Obstetrics and Gynecology, 206(2), 134.e131-138. https://doi.org/10.1016/j.ajog.2011.10.878.CrossRef

Bateman, B. T., Hernandez-Diaz, S., Huybrechts, K. F., Palmsten, K., Mogun, H., Ecker, J. L., & Fischer, M. A. (2012). Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension, 60(4), 913–920. https://doi.org/10.1161/hypertensionaha.112.197095.CrossRefPubMedPubMedCentral

Catov, J. M., Nohr, E. A., Olsen, J., & Ness, R. B. (2008). Chronic hypertension related to risk for preterm and term small for gestational age births. Obstetrics and Gynecology, 112(2 Pt 1), 290–296. https://doi.org/10.1097/AOG.0b013e31817f589b.CrossRefPubMedPubMedCentral

Dietz, P., Bombard, J., Mulready-Ward, C., Gauthier, J., Sackoff, J., Brozicevic, P., … Taylor, A. (2014). Validation of self-reported maternal and infant health indicators in the Pregnancy Risk Assessment Monitoring System. Maternal and Child Health Journal, 18(10), 2489–2498. doi:https://doi.org/10.1007/s10995-014-1487-y.CrossRefPubMedPubMedCentral

Easterling, T. R. (2014). Pharmacological management of hypertension in pregnancy. Seminars in Perinatology, 38(8), 487–495. https://doi.org/10.1053/j.semperi.2014.08.016.CrossRefPubMedPubMedCentral

Hameed, A., Karaalp, I. S., Tummala, P. P., Wani, O. R., Canetti, M., Akhter, M. W., … Elkayam, U. (2001). The effect of valvular heart disease on maternal and fetal outcome of pregnancy. Journal of the American College of Cardiology, 37(3), 893–899.CrossRefPubMed

Hosmer, D. W., & Lemeshow, S. (1992). Confidence interval estimation of interaction. Epidemiology (Cambridge, Mass.), 3(5), 452–456.CrossRef

Jain, L., Ferre, C., & Vidyasagar, D. (1998). Racial differences in outcome of pregnancies complicated by hypertension. Journal of Maternal-Fetal Medicine, 7(1), 23–27. https://doi.org/10.1002/(SICI)1520-6661(199801/02)7:1<23::AID-MFM6>3.0.CO;2-T PubMed

Khedun, S. M., Maharaj, B., & Moodley, J. (2000). Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing? Paediatric Drugs, 2(6), 419–436.CrossRefPubMed

Lapolla, A., Dalfra, M. G., & Fedele, D. (2008). Pregnancy complicated by type 2 diabetes: an emerging problem. Diabetes Research and Clinical Practice, 80(1), 2–7. https://doi.org/10.1016/j.diabres.2007.11.009.CrossRefPubMed

Lin, H. W., Phan, K., & Lin, S. J. (2006). Trends in off-label beta-blocker use: a secondary data analysis. Clinical Therapeutics, 28(10), 1736–1746. https://doi.org/10.1016/j.clinthera.2006.10.015. (Discussion 1710–1731).CrossRefPubMed

Lydakis, C., Lip, G. Y., Beevers, M., & Beevers, D. G. (1999). Atenolol and fetal growth in pregnancies complicated by hypertension. American Journal of Hypertension, 12(6), 541–547.CrossRefPubMed

Magee, L. A., Singer, J., & von Dadelszen, P. (2015). Less-tight versus tight control of hypertension in pregnancy. The New England Journal of Medicine, 372(24), 2367–2368. https://doi.org/10.1056/NEJMc1503870.PubMed

Martin, J. A., Hamilton, B. E., Osterman, M. J., Curtin, S. C., & Matthews, T. J. (2015). Births: Final data for 2013. National Vital Statistics Reports, 64(1), 1–65.

McCormick, M. C. (1985). The contribution of low birth weight to infant mortality and childhood morbidity. The New England Journal of Medicine, 312(2), 82–90. https://doi.org/10.1056/nejm198501103120204.CrossRefPubMed

McCowan, L., & Horgan, R. P. (2009). Risk factors for small for gestational age infants. Best Practice and Research: Clinical Obstetrics and Gynaecology, 23(6), 779–793. https://doi.org/10.1016/j.bpobgyn.2009.06.003.CrossRefPubMed

McCowan, L. M., Buist, R. G., North, R. A., & Gamble, G. (1996). Perinatal morbidity in chronic hypertension. British Journal of Obstetrics and Gynaecology, 103(2), 123–129.CrossRefPubMed

Meidahl Petersen, K., Jimenez-Solem, E., Andersen, J. T., Petersen, M., Brodbaek, K., Kober, L., … Poulsen, H. E. (2012). beta-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. https://doi.org/10.1136/bmjopen-2012-001185.PubMedPubMedCentral

Miranda, M. L., Swamy, G. K., Edwards, S., Maxson, P., Gelfand, A., & James, S. (2010). Disparities in maternal hypertension and pregnancy outcomes: evidence from North Carolina, 1994–2003. Public Health Reports (Washington, D. C.: 1974), 125(4), 579–587.CrossRef

Nakhai-Pour, H. R., Rey, E., & Berard, A. (2010). Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Research Part B, 89(2), 147–154. https://doi.org/10.1002/bdrb.20238.PubMed

Oken, E., & Gillman, M. W. (2003). Fetal origins of obesity. Obesity Research, 11(4), 496–506. https://doi.org/10.1038/oby.2003.69.CrossRefPubMed

Orbach, H., Matok, I., Gorodischer, R., Sheiner, E., Daniel, S., Wiznitzer, A., … Levy, A. (2013). Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. American Journal of Obstetrics and Gynecology, 208(4), e301–306. https://doi.org/10.1016/j.ajog.2012.11.011. 301 .CrossRef

Overpeck, M. D., Hediger, M. L., Zhang, J., Trumble, A. C., & Klebanoff, M. A. (1999). Birth weight for gestational age of Mexican American infants born in the United States. Obstetrics and Gynecology, 93(6), 943–947.PubMed

Reefhuis, J., Gilboa, S. M., Anderka, M., Browne, M. L., Feldkamp, M. L., & Hobbs, C. A. … National Birth Defects Prevention, Study. (2015). The National Birth Defects Prevention Study: A review of the methods. Birth Defects Research Part A, 103(8), 656–669. https://doi.org/10.1002/bdra.23384.CrossRefPubMedPubMedCentral

Rey, E., & Couturier, A. (1994). The prognosis of pregnancy in women with chronic hypertension. American Journal of Obstetrics and Gynecology, 171(2), 410–416.CrossRefPubMed

Roberts, C. L., Ford, J. B., Algert, C. S., Antonsen, S., Chalmers, J., Cnattingius, S., … Weir, C. J. (2011). Population-based trends in pregnancy hypertension and pre-eclampsia: An international comparative study. BMJ Open, 1(1), e000101. https://doi.org/10.1136/bmjopen-2011-000101.CrossRefPubMedPubMedCentral

Sibai, B. M., Lindheimer, M., Hauth, J., Caritis, S., VanDorsten, P., Klebanoff, M., … Dombrowski, M. (1998). Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. The New England Journal of Medicine, 339(10), 667–671. https://doi.org/10.1056/nejm199809033391004.CrossRefPubMed

Su, C. Y., Lin, H. C., Cheng, H. C., Yen, A. M., Chen, Y. H., & Kao, S. (2013). Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: A population-based study. PLoS ONE, 8(2), e53844. https://doi.org/10.1371/journal.pone.0053844.CrossRefPubMedPubMedCentral

van Gelder, M. M., van Rooij, I. A., de Walle, H. E., Roeleveld, N., & Bakker, M. K. (2013). Maternal recall of prescription medication use during pregnancy using a paper-based questionnaire: A validation study in the Netherlands. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 36(1), 43–54. https://doi.org/10.1007/s40264-012-0004-8.CrossRef

von Dadelszen, P., Ornstein, M. P., Bull, S. B., Logan, A. G., Koren, G., & Magee, L. A. (2000). Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: A meta-analysis. Lancet, 355(9198), 87–92.CrossRef

Wallis, A. B., Saftlas, A. F., Hsia, J., & Atrash, H. K. (2008). Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. American Journal of Hypertension: Journal of the American Society of Hypertension, 21(5), 521–526. https://doi.org/10.1038/ajh.2008.20.CrossRef

Xie, R. H., Guo, Y., Krewski, D., Mattison, D., Walker, M. C., Nerenberg, K., & Wen, S. W. (2014). Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. Bjog, 121(9), 1090–1096. https://doi.org/10.1111/1471-0528.12678.CrossRefPubMed

Zhang, J., & Bowes, W. A. Jr. (1995). Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population. Obstetrics and Gynecology, 86(2), 200–208.CrossRefPubMed

Title: Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997–2011
Authors: Sarah C. Fisher
Alissa R. Van Zutphen
Paul A. Romitti
Marilyn L. Browne
for the National Birth Defects Prevention Study
Publication date: 01-02-2018
Publisher: Springer US
Published in: Maternal and Child Health Journal / Issue 2/2018
Print ISSN: 1092-7875
Electronic ISSN: 1573-6628
DOI: https://doi.org/10.1007/s10995-017-2395-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997–2011

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

The Development of the Healthy Pregnancy Stress Scale, and Validation in a Sample of Low-Income African American Women

Maternal Health Behaviors and Outcomes in a Nomadic Tibetan Population

A Pilot Quality Improvement Collaborative to Improve Safety Net Dental Access for Pregnant Women and Young Children

Predictors and Patterns of Psychiatric Treatment Dropout During Pregnancy Among Low-Income Women

Paid Maternity Leave in the United States: Associations with Maternal and Infant Health

Examining Delivery Method and Infant Feeding Intentions between Women in Traditional and Non-Traditional Prenatal Care